Barclays PLC Purchases 14,065 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)

Barclays PLC grew its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) by 7.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 215,424 shares of the company’s stock after buying an additional 14,065 shares during the quarter. Barclays PLC owned approximately 0.17% of Cytek Biosciences worth $1,397,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of CTKB. Sterling Capital Management LLC grew its position in Cytek Biosciences by 799.8% during the 4th quarter. Sterling Capital Management LLC now owns 3,887 shares of the company’s stock worth $25,000 after acquiring an additional 3,455 shares during the last quarter. GAMMA Investing LLC boosted its stake in Cytek Biosciences by 280.3% in the fourth quarter. GAMMA Investing LLC now owns 4,932 shares of the company’s stock worth $32,000 after purchasing an additional 3,635 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Cytek Biosciences by 0.7% during the fourth quarter. Principal Financial Group Inc. now owns 506,925 shares of the company’s stock worth $3,290,000 after purchasing an additional 3,753 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Cytek Biosciences by 111.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,850 shares of the company’s stock valued at $57,000 after buying an additional 4,665 shares in the last quarter. Finally, Olympiad Research LP raised its holdings in shares of Cytek Biosciences by 51.0% in the fourth quarter. Olympiad Research LP now owns 19,601 shares of the company’s stock valued at $127,000 after buying an additional 6,617 shares during the last quarter. Institutional investors and hedge funds own 69.46% of the company’s stock.

Cytek Biosciences Stock Up 4.3 %

Cytek Biosciences stock opened at $3.86 on Friday. The stock has a market cap of $494.45 million, a price-to-earnings ratio of -48.24 and a beta of 1.41. Cytek Biosciences, Inc. has a 12-month low of $3.27 and a 12-month high of $7.63. The business’s 50-day simple moving average is $4.00 and its 200 day simple moving average is $5.31.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Stephens reissued an “overweight” rating and set a $6.00 price objective on shares of Cytek Biosciences in a report on Wednesday, March 19th. The Goldman Sachs Group set a $5.25 price target on shares of Cytek Biosciences in a research note on Sunday, February 2nd. Finally, Piper Sandler dropped their price objective on shares of Cytek Biosciences from $8.50 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, March 4th.

Cytek Biosciences Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.